Observation of severe pediatric inflammatory multisystem syndrome associated with COVID-19
- Authors: Efremova O.S.1, Bregel L.V.1, Rudenko N.Y.2, Kniazeva N.A.2, Kostik M.M.3
-
Affiliations:
- Irkutsk State Medical Academy of Postgraduate Education, branch of Russian Medical Academy of Continuous Professional Education
- Irkutsk State Regional Children’s Clinical Hospital
- St. Petersburg State Pediatric Medical University
- Issue: Vol 14, No 1 (2023)
- Pages: 127-134
- Section: Clinical observation
- URL: https://journals.eco-vector.com/pediatr/article/view/340774
- DOI: https://doi.org/10.17816/PED141127-134
- ID: 340774
Cite item
Abstract
One of the rare manifestations of COVID-19 is pediatric inflammatory multisystem syndrome, most often in publications it is found out how pediatric inflammatory multisystem syndrome in children (РIMS). The progression of the inflammatory response in РIMS may be a consequence of the development of secondary hemophagocytic syndrome, a significant part of which is refractory fever, an increase in ferritin, AST and ALT, cytopenia, an increase in interleukin 6, severe hepatic and neurological dysfunction. The case with this group of representatives of other multiple organ failure manifestations in the detection of acute distress syndrome and acute heart failure, in the detection of the development of myocarditis.
A feature of the described clinical detection is the dynamic observation of a severe pediatric multisystem inflammatory syndrome associated with COVID-19, complicated by myocarditis with acute heart failure, left ventricular dysfunction and secondary hemophagocytic syndrome, in an 11-year-old girl with underlying obesity. The child is taking triple therapy with glucocorticosteroids in combination with intravenous immunoglobulin and cyclosporine A, with an expected effect on the ongoing treatment. Possible features of observation are noted: 1) a very early start of РIMS during the acute phase of СOVID-19; 2) transient dyslipidemia at the onset of РIMS with an increase in cholesterol, mainly due to the low-density lipoprotein fraction, and spontaneous regression without lipid-lowering drugs; 3) MRI signs of myocarditis in a month after the onset of the disease, despite the normalization of echocardiography and pro-BNP.
Full Text

About the authors
Olesya S. Efremova
Irkutsk State Medical Academy of Postgraduate Education, branch of Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: shaguno@mail.ru
ORCID iD: 0000-0001-7066-9138
assistant of the Department of pediatrics, cardiologist
Russian Federation, IrkutskLyudmila V. Bregel
Irkutsk State Medical Academy of Postgraduate Education, branch of Russian Medical Academy of Continuous Professional Education
Email: loudmilabregel@yandex.ru
ORCID iD: 0000-0002-7668-1282
MD, PhD, Dr. Sci. (Med.), professor, head of the Department of pediatrics
Russian Federation, IrkutskNatalia Yu. Rudenko
Irkutsk State Regional Children’s Clinical Hospital
Email: nata.rudenko.65@inbox.ru
ORCID iD: 0000-0001-5795-6992
deputy chief medical officer
Russian Federation, IrkutskNatalya A. Kniazeva
Irkutsk State Regional Children’s Clinical Hospital
Email: nata.rudenko.65@inbox.ru
ORCID iD: 0000-0002-9099-6803
anesthesiologist
Russian Federation, IrkutskMikhail M. Kostik
St. Petersburg State Pediatric Medical University
Email: kost-mikhail@yandex.ru
ORCID iD: 0000-0002-1180-8086
MD, PhD, Dr. Sci. (Med.), professor of the Department of hospital pediatrics
Russian Federation, Saint PetersburgReferences
- Minzdrav Rossii. Metodicheskie rekomendatsii “Osobennosti klinicheskikh proyavlenii i lecheniya zabolevaniya, vyzvannogo novoi koronavirusnoi infektsiei (COVID-19) u detei”. Versiya 2. (In Russ.) 3 July 2020.
- Buda P, Strauss E, Januszkiewicz-Lewandowska D, et al. Clinical characteristics of children with MIS-C fulfilling classification criteria for macrophage activation syndrome. Front Pediatr. 2022;10:981711. doi: 10.3389/fped.2022.98171
- Cena H, Fiechtner L, Vincenti A, et al. COVID-19 pandemic as risk factors for excessive weight gain in pediatrics: The role of changes in nutrition behavior. A Narrative Review. Nutrients. 2021;13(12):4255. doi: 10.3390/nu13124255
- Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383:347–358. doi: 10.1056/NEJMoa2021756
- Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334. doi: 10.1056/NEJMoa2021680
- Gowin E, Toczyłowski K, Sulik A, et al. The role of glucocorticoids in the treatment of multisystem inflammatory syndrome (MIS-C)-data from POLISH MIS-C Registry. Children (Basel). 2022;9(2):178. doi: 10.3390/children9020178
- Grzegorowska O, Lorkowski J. Possible Correlations between Atherosclerosis, Acute Coronary Syndromes and COVID-19. J Clin Med. 2020;9(11):3746. doi: 10.3390/jcm9113746
- Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 1. Arthritis Rheumatol. 2020;72(11):1791. doi: 10.1002/art.41454
- Henter J-I, Horne AC, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131. doi: 10.1002/pbc.21039
- Supriya J, Sheila NM, Aalok SR, et al. Myocarditis in multisystem inflammatory syndrome in children associated with coronavirus disease 2019. Cardiol Rev. 2020;28(6): 308–311. doi: 10.1097/CRD.0000000000000341
- McMurray JC, May JW, Cunningham MW, Jones OY. Multisystem inflammatory syndrome in children (MIS-C), a post-viral myocarditis and systemic vasculitis — a critical review of its pathogenesis and treatment. Front Pediatr. 2020;8:626182. doi: 10.3389/fped.2020.626182
- Ravelli A, Minoia F, Davì S, et al. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open. 2016;2(1): e000161. doi: 10.1136/rmdopen-2015-000161
- Saha S, Pal P, Mukherjee D. Neonatal MIS-C: managing the cytokine storm. Pediatrics. 2021;148(5): e2020042093. doi: 10.1542/peds.2020-042093
- Knox SK, Mahr TA. Treatment of multisystem inflammatory syndrome in children. Pediatrics. 2022;150(S3): S67. doi: 10.1542/peds.2022-059346WWWW
- Shi Z, Jiang Y, Weir-McCall J, et al. COVID-19 and atherosclerosis: looking beyond the acute crisis. Emergency Crit Care Med. 2022;2(1):1–4. doi: 10.1097/EC9.0000000000000031
- Son MBF, Berbert L, Young C, et al. Postdischarge glucocorticoid use and clinical outcomes of multisystem inflammatory syndrome in children. JAMA Netw Open. 2022;5(11): e2241622. doi: 10.1001/jamanetworkopen.2022.41622
- Vinciguerra M, Romiti S, Sangiorgi GM, et al. SARS-CoV-2 and atherosclerosis: should COVID-19 be recognized as a new predisposing cardiovascular risk factor? J Cardiovasc Dev Dis. 2021;8(10):130. doi: 10.3390/jcdd8100130
- Wu EY, Campbell MJ. Cardiac manifestations of multisystem inflammatory syndrome in children (MIS-C) following COVID-19. Curr Cardiol Rep. 2021;23(11):168. doi: 10.1007/s11886-021-01602-3
